Inovio Pharma’s Ebola vaccine moving into Ph I with GeneOne Life Science
US drug developer Inovio Pharmaceuticals (NYSE MKT: INO) has said it will advance its DNA vaccine for Ebola into a Phase I clinical trial in a collaboration with South Korea-based GeneOne Life Science (KRX: 011000), an international DNA vaccine manufacturer in which Inovio holds a minority interest.
The companies are currently conducting pre-Investigational New Drug (IND) activities and plan to start the clinical study in the first half of 2015. On successful completion of the Phase I, the companies will jointly seek additional third party support and resources to further develop and commercialize this product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze